Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

BACKGROUND: In patients with melanoma and asymptomatic brain metastases (MBM), nivolumab plus ipilimumab provided an intracranial response rate of 55%. Here, we present the first report for patients who were symptomatic and/or required corticosteroids and updated data for asymptomatic patients. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Tawbi, Hussein A, Forsyth, Peter A, Hodi, F Stephen, Lao, Christopher D, Moschos, Stergios J, Hamid, Omid, Atkins, Michael B, Lewis, Karl, Thomas, Reena P, Glaspy, John A, Jang, Sekwon, Algazi, Alain P, Khushalani, Nikhil I, Postow, Michael A, Pavlick, Anna C, Ernstoff, Marc S, Reardon, David A, Puzanov, Igor, Kudchadkar, Ragini R, Tarhini, Ahmad A, Sumbul, Anne, Rizzo, Jasmine I, Margolin, Kim A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563325/
https://www.ncbi.nlm.nih.gov/pubmed/33880555
http://dx.doi.org/10.1093/neuonc/noab094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563325/
https://www.ncbi.nlm.nih.gov/pubmed/33880555
http://dx.doi.org/10.1093/neuonc/noab094

Ejemplares similares